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and surgeries in patients eventually 
diagnosed with benign adrenal masses. 
In view of our findings, work on the 
timely revision of the international 
guidelines on the management of 
adrenal incidentalomas2 is underway.
Our study1 also provides a definitive 
prospective validation of urine steroid 
metabolomics—the combination of 
mass spectrometry-based multisteroid 
profiling with steroid data analysis by a 
machine learning-based algorithm. We 
showed that urine steroid metabolomics 
had twice the positive predictive value 
of either tumour diameter or imaging 
characteristics including unenhanced 
tumour attenuation in the detection 
of adrenocortical carcinoma and 
that the combination of these three 
tests provided the highest diagnostic 
accuracy, which should be reflected 
in future international guideline 
recommendations. 
Impaired kidney function was not 
an explicit exclusion criterion for 
enrolment in the EURINE-ACT study. 
However, we do not anticipate that 
chronic kidney disease will compromise 
the diagnostic accuracy of our 
approach, except in patients on kidney 
replacement therapy. Steroid profiling 
in patients with chronic kidney disease 
previously showed minor changes 
affecting glucocorticoid metabolism,3 
which are unlikely to affect test results. 
Diagnostic assessment by urine steroid 
metabolomics is based on the detection 
of changes in the pattern of steroid 
excretion, specifically the propensity 
of adrenocortical carcinomas to 
overproduce a distinct set of precursor 
steroids, rather than absolute 
quantitative cutoffs for individual 
steroid metabolites that might or 
might not be affected by impaired renal 
function.
We excluded any patients taking 
drugs that could affect steroid 
biosynthesis and metabolism. In clinical 
practice, intake of glucocorticoids 
and inhibitors of key branch points of 
steroidogenesis, such as ketoconazole 
and metyrapone, could affect the 
accuracy of our approach. However, 
steroid metabolite secretion in the 
urine.
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Authors’ reply
We are grateful to Panagiota Anyfanti 
and colleagues for their interest in 
our work1 and their useful comments. 
We agree that our findings with 
respect to the unenhanced CT tumour 
attenuation threshold should have 
a major impact on clinical practice. 
These results, based on data from more 
than 2000 prospectively recruited 
participants, justify an immediate 
change in practice, with maximum 
tumour diameter of 4 cm and 
unenhanced CT tumour attenuation 
of 20 Hounsfield units (HU) as the 
most appropriate threshold values 
for consideration of adrenocortical 
carcinoma as a differential diagnosis in 
patients with newly diagnosed adrenal 
masses. We showed that, compared 
with the currently recommended cutoff 
of 10 HU, a tumour attenuation value 
greater than 20 HU on unenhanced 
CT had considerably higher specificity 
(80·0% [95% CI 77·9–82·0%] vs 64·0% 
[61·4–66·4]) while maintaining similar 
sensitivity (99·0% [94·4–100·0] vs 
100·0% [96·3–100·0]). Introducing 
a more specific cutoff into clinical 
practice should result in a decrease in 
the number of imaging procedures 
improved diagnostic accuracy provided 
by the dual combination of tumour 
diameter and imaging characteristics, 
which is currently the most widely used 
approach in clinical practice, with an 
unenhanced CT tumour attenuation 
threshold of 20 Hounsfield units 
(HU) instead of the recommended 
10 HU, is the more directly relevant 
and clinically practical finding from 
the study. Indeed, there remains a 
long way to go before assessment 
of urine steroid metabolomics with 
mass spectrometry could be routinely 
implemented in clinical practice. In 
addition to the limitations discussed 
in the accompanying commentary,2 
we are concerned about the cost-
effectiveness of such an approach, 
which will require more affordable 
mass spectrometry to be available in 
clinical laboratories. Furthermore, the 
incorporation of steroid metabolomics 
into clinical practice will require 
validation of assay reproducibility 
and the subsequent introduction of 
population-based, age-specific, and 
sex-specific reference values for the 
adult steroid metabolome.3 
Additionally, we note that patients 
with current or recent (<6 months) 
intake of drugs known to alter 
steroid synthesis or metabolism 
were excluded from the study. Could 
the investigators specify which drug 
categories were included in this 
exclusion criterion? Treatment with 
systemic glucocorticoids or drugs 
known to alter steroid secretion, such 
as hormonal menopause treatment, 
antiepileptic drugs, ketoconazole, 
and mineralocorticoid receptor 
antagonists (spironolactone or 
eplerenone) might compromise the 
diagnostic perfor mance of urine 
metabolomics.3,4 However, use 
of these drugs is not uncommon 
among individuals of a similar age to 
those included in the study (median 
age 59 years). Finally, we would be 
grateful if the investi gators could 
provide information on participants’ 
renal function, since advanced 
chronic kidney disease might affect 
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Tackling the COVID-19 
pandemic in paradise: 
the Mauritian experience
Mauritius is a subtropical island located 
in the southwestern Indian Ocean, with 
a multiethnic population of about 
1·3 million people. Mauritius also 
has one of the highest prevalences of 
diabetes worldwide,1 a condition linked 
to the severity of COVID-19.2
Despite the challenges in curbing the 
COVID-19 pandemic, Mauritius scored a 
very high mark on the Oxford COVID-19 
Government Response Stringency 
Index3 in the middle of April, 2020. In 
part, this success was due to a prompt 
and consistent governmental strategy. 
On Jan 21, all passengers arriving 
from China were quarantined 
for 14 days under strict sanitary 
conditions. 1 day later, the Prime 
Minister of Mauritius chaired a high-
level committee meeting with all his 
ministers, as well as a representative 
from WHO to discuss approaches 
to control the pandemic. Because 
Mauritius is a very popular tourist 
destination, it was vital to control the 
arrival of overseas travellers with COVID 
infection. Temperature checks for 
passengers arriving at the international 
airport were introduced, and all visitors 
from high risk countries (eg, Singapore, 
Malaysia, and Thailand) were also 
quarantined from Feb 11.
On March 18, the first three cases of 
COVID-19 were registered in travellers 
and consequently on March 19, the 
borders were closed. With the escalation 
of cases, a curfew was imposed on March 
20, and eventually a complete lock down 
was implemented on March 24.
Mauritius and its citizens also stood 
firm against the pandemic. Work 
access permits were essential to avoid 
heavy fines and legal action. Health 
services were fully functional including 
a hotline telephone service to answer 
public queries. Between March 21, and 
July 20, 99 678 calls were received and 
attended to. A home visit team was set 
up which provided domiciliary visits 
consultations, and basic treatment. A 
mobile application, beSafeMoris was 
launched on March 26, allowing the 
Mauritian population to obtain real-
time information about health and 
safety measures.
In parallel, regional public health 
superintendents and several rapid 
response teams were responsible for 
the transfer of patients with suspected 
COVID-19 to quarantine and treatment 
centres and a contact tracing team 
aimed to identify related cases. WHO 
infection control standard precautions 
were strictly followed during the 
pandemic.4
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we have previously shown4 that 
mitotane treatment does not affect 
the malignant steroid fingerprint and 
recently provided proof of principle for 
the use of urine steroid metabolomics 
for recurrence detection in patients 
with completely resected adrenocortical 
carcinoma.5
The machine learning-based 
algorithm we used for the diagnostic 
interpretation of urine steroid profiling 
results was developed from data from 
a retrospectively collected cohort of 
patients with adrenocortical adenomas 
and carcinomas,6 prior to its prospective 
validation in the EURINE-ACT study.1 
Age-based and sex-based reference 
ranges are irrelevant to the diagnostic 
use of our algorithm. In our previous 
proof-of-principle study6 on the use 
of urine steroid metabolomics for the 
differentiation of benign and malignant 
adrenocortical tumours, we showed 
that the malignant steroid fingerprint 
detected in patients with adrenocortical 
carcinoma is orders of magnitude higher 
than the relatively minor differences 
in steroid metabolite excretion seen 
between sexes and adult age groups.
We acknowledge that global rollout of 
urine steroid metabolomics will depend 
on the regional availability of mass 
spectrometry technology, but we are 
confident that its rollout across Europe 
can be achieved fairly soon, primarily 
implemented through a network 
of expert laboratories delivering 
centralised service provision and 
maintaining quality control through 
cross-validation and certification.
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